Novo Nordisk Wegovy HD Approved with 20% Weight Loss
BAGSVÆRD, Denmark, March 19, 2026 Novo Nordisk A/S announced that the U.S. Food and Drug Administration (FDA) has approved...
Obesity treatment
Advertisement
Genentech Reports Positive Phase II Results for Petrelintide
SOUTH SAN FRANCISCO, California – March 6, 2026 Genentech announced positive topline results from the Phase II ZUPREME-1 clinical...
Cipla Launches Generic Liraglutide in US
MUMBAI, India & WARREN, N.J., USA – February 27, 2026 Cipla Limited announced the U.S. launch of Liraglutide Injection...
Ascletis Expands ASC30 Oral GLP-1 Program for Obesity Treatment
Hong Kong, January 26, 2026 — Ascletis Pharma continued progress in the clinical development of ASC30, its investigational oral...
Lilly’s Oral GLP-1 Orforglipron Sustains Weight Loss in Phase 3 Trial
Indianapolis, December 18, 2025 — Eli Lilly and Company announced positive topline results from its first-of-its-kind Phase 3 ATTAIN-MAINTAIN...
Advertisements
Lilly’s Retatrutide Achieves Major Gains in Weight and Pain Relief
INDIANAPOLIS, December 11, 2025 — Eli Lilly and Company announced positive topline results from the Phase 3 TRIUMPH-4 trial,...
EndoZip™ Begins Pivotal Trial to Advance Automated ESG in U.S.
CAESAREA, Israel, Dec. 10, 2025 — Nitinotes Ltd., an early commercial-stage medical technology company developing fully automated endoluminal suturing...
Mazdutide 9mg Enters NMPA Review, Advancing Obesity Treatment
BEIJING, China, Nov. 25, 2025 — Innovent Biologics and Eli Lilly announced that the supplementary application for Mazdutide 9mg...
Wave Life Sciences’ RNA Breakthrough Targets Obesity and Liver Disorders
BOSTON, October 29, 2025 — Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology leader in RNA medicines, has...
Lilly Invests $6.5 B to Build API Plant in Houston
Houston, Texas – September 23, 2025 — Eli Lilly and Company (NYSE: LLY) will invest $6.5 billion to build...
Advertisement
